Zhiyu Tang
Fujian Medical University(CN)Peking University(CN)Peking University People's Hospital(CN)Flometrics (United States)(US)
Publications by Year
Research Areas
Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Melanoma and MAPK Pathways, Chronic Myeloid Leukemia Treatments, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL(2019)360 cited
- → Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase(2019)338 cited
- → The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions(2018)279 cited
- → Hyperspectral imaging combined with machine learning as a tool to obtain high‐throughput plant salt‐stress phenotyping(2019)132 cited
- → Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors(2020)106 cited
- → Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor(2020)95 cited